Rosiglitazone reduces diabetes angiopathy by inhibiting mitochondrial dysfunction dependent on regulating HSP22 expression
Summary: The effects of rosiglitazone (RSG) in patients with type 2 diabetes mellitus (T2DM) remain controversial. Here, we first used network pharmacology to identify the common targets of RSG in the treatment of diabetes angiopathy (DA). Enrichment analysis found that the common genes were involve...
Main Authors: | Lingling Yu, Shengsong Chen, Qian Liang, Chahua Huang, Weifang Zhang, Longlong Hu, Yun Yu, Liang Liu, Xiaoshu Cheng, Huihui Bao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-04-01
|
Series: | iScience |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004223002717 |
Similar Items
-
Rosiglitazone Protects Endothelial Cells From Irradiation-Induced Mitochondrial Dysfunction
by: Bjorn Baselet, et al.
Published: (2020-03-01) -
Leukemia and rosiglitazone
by: Irfan Yavasoglu, et al.
Published: (2016-03-01) -
Protective Effects and Mechanisms of Vaccarin on Vascular Endothelial Dysfunction in Diabetic Angiopathy
by: Fei Xu, et al.
Published: (2019-09-01) -
Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington’s Disease
by: Marta Tomczyk, et al.
Published: (2022-08-01) -
Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats
by: Onyia Jude E, et al.
Published: (2010-05-01)